Search Result

Isoforms Recommended:	CYP17A1

Results for "

CYP17A1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Androgen Receptor (3) Cytochrome P450 (12) Drug Metabolite (4) Endogenous Metabolite (1) HDAC (1) Isotope-Labeled Compounds (1) PI3K (1) Small Interfering RNA (siRNA) (1)
By Research Areas:	Cancer (16) Cardiovascular Disease (1) Metabolic Disease (1)
Oligonucleotides:	Pre-designed siRNA Sets (1) siRNAs (1)

Inhibitors & Agonists

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-148375

Abiraterone sulfate	Drug Metabolite	Others
Abiraterone sulfate is a metabolite of Abiraterone (HY-148377). Abiraterone is a potent and irreversible CYP17A1 inhibitor with antiandrogen activity .

HY-75054

Abiraterone acetate 15+ Cited Publications CB7630	Cytochrome P450	Cancer
Abiraterone acetate (CB7630) is an oral, potent, selective, and irreversible inhibitor of *CYP17A1* with antiandrogen activity. Abiraterone acetate is a proagent form of Abiraterone (CB7598).

HY-RS03437

CYP17A1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CYP17A1 Human Pre-designed siRNA Set A contains three designed siRNAs for CYP17A1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CYP17A1 Human Pre-designed siRNA Set A CYP17A1 Human Pre-designed siRNA Set A

HY-163359

CYP17A1/HDAC6-IN-1	Cytochrome P450 HDAC	Cancer
CYP17A1/HDAC6-IN-1 (compound 12) is a potent inhibitor of CYP17A1/HDAC6, with IC₅₀ of 0.284μM and 0.6015 μM,respectively. CYP17A1/HDAC6-IN-1 has anti-tumor activity .

HY-116643

SU 10603	Cytochrome P450	Metabolic Disease
SU 10603 is a specific inhibitor of P45017α (P450c17; CYP17A1) .

HY-117529

BMS-351	Cytochrome P450	Cancer
BMS-351 (compound 18) is a potent, oral active, nonsteroidal CYP17A1 lyase inhibitor with the IC₅₀ values of 19 nM and 4 nM aganist human CYP17A1 and cynomolgus monkeys CYP17A1,respectively. BMS-351 can be used for the study of castration-resistant prostate cancer .

HY-155666

YXG-158	Androgen Receptor	Cancer
YXG-158 (Compound 23-h) is an orally active AR degrader and *CYP17A1* inhibitor. YXG-158 has AR degradation activity with DC₅₀ value of 1.28 μM. YXG-158 can inhibit CYP17A1 with IC₅₀ value of 100 nM. XG-158 can be used for the research of enzalutamide-resistant prostate cancer .

HY-148376

Abiraterone N-oxide	Drug Metabolite	Cancer
Abiraterone N-oxide is a metabolite of Abiraterone (HY-148377). Abiraterone is a potent and irreversible CYP17A1 inhibitor with antiandrogen activity .

HY-164457

ASN-001	Cytochrome P450	Cancer
ASN-001 is an orally active *CYP-17A1* lyase inhibitor that selectively inhibits testosterone synthesis. ASN-001 has anticancer activity and can be used for research in the field of prostate cancer .

HY-111421

ODM-204	Androgen Receptor Cytochrome P450	Cancer
ODM-204 is novel nonsteroidal dual inhibitor of both androgen receptor and CYP17A1 enzyme, with IC₅₀s of 80 nM and 22 nM, respectively.

HY-103687

Abiraterone metabolite 1 3β-OH-5α-Abi	Drug Metabolite	Cancer
Abiraterone metabolite 1 is a 5β-reduced metabolite of abiraterone. Abiraterone, a steroidal agent, inhibits CYP17A1, blocks androgen synthesis and prolongs survival in prostate cancer.

HY-75054S

Abiraterone acetate-d4 CB7630-d₄	Isotope-Labeled Compounds Cytochrome P450	Cancer
Abiraterone acetate-d₄ is the deuterium labeled Abiraterone acetate. Abiraterone acetate (CB7630) is an oral, potent, selective, and irreversible inhibitor of CYP17A1 with antiandrogen activity. Abiraterone acetate is a proagent form of Abiraterone (CB7598).

HY-137193

5,6-Dihydroabiraterone	Drug Metabolite	Cancer
5,6-Dihydroabiraterone is the metabolism of Abiraterone (HY-70013). Abiraterone is a potent and irreversible CYP17A1 inhibitor with antiandrogen activity, and shows antitumor activity in CRPC (castration-resistant prostate cancer) .

HY-75054R

Abiraterone acetate (Standard) 15+ Cited Publications CB7630 (Standard)	Cytochrome P450	Cancer
Abiraterone acetate (Standard) is the analytical standard of Abiraterone acetate. This product is intended for research and analytical applications. Abiraterone acetate (CB7630) is an oral, potent, selective, and irreversible inhibitor of *CYP17A1* with antiandrogen activity. Abiraterone acetate is a proagent form of Abiraterone (CB7598).

HY-70013

Abiraterone Maximum Cited Publications 18 Publications Verification CB-7598	Cytochrome P450	Cancer
Abiraterone is a potent and irreversible *CYP17A1* inhibitor with antiandrogen activity, which inhibits both the 17α-hydroxylase and 17,20-lyase activity of the cytochrome p450 enzyme CYP17 with IC₅₀s of 2.5 nM and 15 nM, respectively.

HY-109619

D4-abiraterone Δ4-Abiraterone; CB-7627; Abiraterone D4A metabolite	Androgen Receptor Cytochrome P450	Cancer
D4-abiraterone is a major metabolite of abiraterone. D4-abiraterone is an inhibitor of *CYP17A1, 3b-hydroxysteroid dehydrogenase (3βHSD) and steroid-5a-reductase (SRD5A) and also an antagonist of androgen receptor*.

HY-70013R

Abiraterone (Standard)	Cytochrome P450	Cancer
Abiraterone (Standard) is the analytical standard of Abiraterone. This product is intended for research and analytical applications. Abiraterone is a potent and irreversible *CYP17A1* inhibitor with antiandrogen activity, which inhibits both the 17α-hydroxylase and 17,20-lyase activity of the cytochrome p450 enzyme CYP17 with IC₅₀s of 2.5 nM and 15 nM, respectively.

HY-W741510

21-Deoxy Cortisone 21-Desoxycortisone; NSC 38722	Endogenous Metabolite	Cardiovascular Disease
21-Deoxy Cortisone (21-Desoxycortisone; NSC 38722) is a corticosteroid metabolite of 11-ketoprogesterone. It is formed from 11-ketoprogesterone by the cytochrome P450 (CYP) isozyme CYP17A1, but can also be produced by oxidation of 21-deoxycortisone (HY-113405) by 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2). Congenital adrenal hyperplasia is an inborn error of metabolism characterized by a deficiency of 21-hydroxylase, and 21-Deoxy Cortisone levels are elevated in patients with congenital adrenal hyperplasia.

HY-101516

*CYP17-IN-1*	Cytochrome P450	Cancer
CYP17-IN-1 (compound 9c) is a potent and orally active *CYP17* inhibitor against rat and human CYP17 with IC₅₀s of 15.8 and 20.1 nM .

HY-W636234

GSK2636771 methyl	PI3K	Cancer
GSK2636771 methyl (compound II) is an inhibitor of PI3Kβ. GSK2636771 methyl can be used in the research of cancer combined with VT-464 (HY-15996) .

Abiraterone acetate-d4
Abiraterone acetate-d₄ is the deuterium labeled Abiraterone acetate. Abiraterone acetate (CB7630) is an oral, potent, selective, and irreversible inhibitor of CYP17A1 with antiandrogen activity. Abiraterone acetate is a proagent form of Abiraterone (CB7598).

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80640

	*Cytochrome P450 17A1* Antibody (YA786)** CPT7; CYP17; P450C17; S17AH; CYP17A1	WB	Human
	Cytochrome P450 17A1 Antibody (YA786) is a non-conjugated and Mouse origined monoclonal antibody about 57 kDa, targeting to Cytochrome P450 17A1 (6E1). It can be used for WB assays with tag free, in the background of Human.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

CYP17A1 Human Pre-designed siRNA Set A		siRNAs Pre-designed siRNA Sets
CYP17A1 Human Pre-designed siRNA Set A contains three designed siRNAs for CYP17A1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.